Advisory Research Inc Corcept Therapeutics Inc Transaction History

Advisory Research Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $3,705 - $4,368	150 Added 0.6%	25,087 $643,000
Q2 2022 Aug 17, 2022	BUY	$17.33 - $25.3 $432,158 - $630,906	24,937 New	24,937 $593,000
Q1 2018 May 15, 2018	SELL	$14.59 - $25.5 $939,931 - $1.64 Million	-64,423 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$15.77 - $20.72 $211,286 - $277,606	13,398 Added 26.26%	64,423 $1.16 Million
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $627,607 - $984,782	51,025	51,025 $985,000

349

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.32B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.